Fundraising Fox

Verastem

NASDAQ: VSTM

Needham, US · Founded 2010 · Massachusetts corporation · 180 employees on LinkedIn · 7 known investors

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.

Founders & leadership

Verastem was founded in 2010 by Robert Weinberg.

RWRobert Weinberg
Robert Weinberg
AC
AMY C. CAVERSExecutive
CC
CATHY CAREWExecutive
JP
JONATHAN PACHTERExecutive
RG
ROB GAGNONExecutive
BSBRIAN STUGLIK
BRIAN STUGLIKExecutive
DPDAN PATERSON
DAN PATERSONExecutive
RF
ROBERT FORRESTERNamed on SEC filing
JG
JOHN GREENNamed on SEC filing
HT
HENRI TERMEERNamed on SEC filing
LP
LOUISE PHANSTIELNamed on SEC filing
RA
RICHARD ALDRICHNamed on SEC filing

Investors · 7

Reported raises · per SEC filings

Form D private placements

$108.7M disclosed across 3 rounds · 2014–2020

$100MraisedMar 2020 · 21 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • BRIAN STUGLIKExecutive Officer, Director
  • BRUCE WENDELDirector
  • ERIC ROWINSKYDirector
  • ALISON LAWTONDirector
  • TIMOTHY BARBERICHDirector
  • MICHAEL KAUFFMANDirector
  • DAN PATERSONExecutive Officer
  • GINA CONSYLMANDirector
  • ROB GAGNONExecutive Officer
Offering amount
$100M
Amount sold
$100M
Sales commissions
$6M
Placement agents
H.C.WAINWRIGHT & CO., LLC, JEFFERIES LLC, CANTOR FITZGERALD & CO.
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
$4.8MraisedJan 2020 · 4 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • TIMOTHY BARBERICHDirector
  • ALISON LAWTONDirector
  • ERIC ROWINSKYDirector
  • BRUCE WENDELDirector
  • GINA CONSYLMANDirector
  • MICHAEL KAUFFMANDirector
  • AMY C. CAVERSExecutive Officer
  • CATHY CAREWExecutive Officer
  • JONATHAN PACHTERExecutive Officer
  • ROB GAGNONExecutive Officer
  • BRIAN STUGLIKExecutive Officer, Director
  • DAN PATERSONExecutive Officer
Offering amount
$4.8M
Amount sold
$4.8M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
$3.9MraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL KAUFFMANDirector
  • ROBERT FORRESTERExecutive Officer, Director
  • JOHN GREENExecutive Officer
  • CHRISTOPH WESTPHALExecutive Officer, Director
  • DAN PATERSONExecutive Officer
  • HENRI TERMEERDirector
  • JONATHAN PACHTERExecutive Officer
  • LOUISE PHANSTIELDirector
  • RICHARD ALDRICHDirector
  • MONICA SINGHExecutive Officer
  • JOANNA HOROBINExecutive Officer
  • STEPHEN SHERWIN, M.D.Director
  • JOHN K. CLARKEDirector
  • ALISON LAWTONDirector
Offering amount
$3.9M
Amount sold
$3.9M
First sale
Feb 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Companies competing with Verastem for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Verastem do?
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
Who founded Verastem?
Verastem was founded by Robert Weinberg in 2010.
Who are Verastem's investors?
Verastem's investors include Bessemer Venture Partners, Cardinal Partners, Foresite Capital, Lightstone Ventures, Longwood Fund, Oberland Capital, OrbiMed.
How much funding has Verastem raised?
Verastem has disclosed $108.7M raised across 3 rounds.
Where is Verastem headquartered?
Verastem is headquartered in Needham, US.